Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From presentation to paper: Gender disparities in oncological research.
Dijksterhuis WPM, Stroes CI, Tan WL, Ithimakin S, Calles A, van Oijen MGH, Verhoeven RHA, Barriuso J, Oosting SF, Ivankovic DK, Furness AJS, Bozovic-Spasojevic I, Gomez-Roca C, van Laarhoven HWM. Dijksterhuis WPM, et al. Int J Cancer. 2020 Jun 1;146(11):3011-3021. doi: 10.1002/ijc.32660. Epub 2019 Oct 11. Int J Cancer. 2020. PMID: 31472016 Free PMC article.
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.
Blay JY, Cropet C, Mansard S, Loriot Y, De La Fouchardière C, Haroche J, Topart D, Tougeron D, You B, Italiano A, Le Brun-Ly V, Ferrero JM, Penel N, Fabbro M, Troussard X, Malka D, Ray-Coquard I, Leboulleux S, Fléchon A, Maubec E, Charles J, Dalle S, Taieb S, Garcia GCTE, Mandache AM, Colignon N, Gavrel M, Nowak F, Hoog Labouret N, Mahier Aït Oukhatar C, Gomez-Roca C. Blay JY, et al. Among authors: gomez roca c. ESMO Open. 2023 Dec;8(6):102038. doi: 10.1016/j.esmoop.2023.102038. Epub 2023 Nov 1. ESMO Open. 2023. PMID: 37922690 Free PMC article.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Gyawali B, et al. ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20. ESMO Open. 2021. PMID: 33887690 Free PMC article. Review.
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.
Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Moreno García V, et al. Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24. Clin Cancer Res. 2014. PMID: 25252757
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I. Hassan R, et al. Cancer. 2020 Nov 15;126(22):4936-4947. doi: 10.1002/cncr.33145. Epub 2020 Sep 1. Cancer. 2020. PMID: 32870522 Free PMC article. Clinical Trial.
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Drakaki A, et al. Among authors: gomez roca c. Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. Clin Cancer Res. 2023. PMID: 37651261 Clinical Trial.
Emerging new anticancer therapies in 2013.
Gomez-Roca C, Delord JP. Gomez-Roca C, et al. Curr Opin Oncol. 2014 May;26(3):357-62. doi: 10.1097/CCO.0000000000000081. Curr Opin Oncol. 2014. PMID: 24709976 Review.
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.
Balança CC, Scarlata CM, Michelas M, Devaud C, Sarradin V, Franchet C, Martinez Gomez C, Gomez-Roca C, Tosolini M, Heaugwane D, Lauzéral-Vizcaino F, Mir-Mesnier L, Féliu V, Valle C, Pont F, Ferron G, Gladieff L, Motton S, Tanguy Le Gac Y, Dupret-Bories A, Sarini J, Vairel B, Illac C, Siegfried-Vergnon A, Mery E, Fournié JJ, Vergez S, Delord JP, Rochaix P, Martinez A, Ayyoub M. Balança CC, et al. Cancer Immunol Res. 2020 Jul;8(7):869-882. doi: 10.1158/2326-6066.CIR-19-0855. Epub 2020 Apr 15. Cancer Immunol Res. 2020. PMID: 32295784
87 results